PMID- 10403010 OWN - NLM STAT- MEDLINE DCOM- 19990820 LR - 20161021 IS - 0125-877X (Print) IS - 0125-877X (Linking) VI - 17 IP - 1 DP - 1999 Mar TI - Effect of IVIG on the hair regrowth in a common variable immune deficiency patient with alopecia universalis. PG - 59-62 AB - Common variable immune deficiency (CVID) is associated with a variety of autoimmune diseases. Alopecia universalis (AU), believed to have an autoimmune basis, has been found in 1.6% of patients with CVID. Intravenous immunoglobulin (IVIG) therapy is used in various immunodeficiency disorders including CVID, and benefit has been shown in the therapy of autoimmune diseases. We report a patient with CVID and AU treated with IVIG who experienced significant hair regrowth. An 8-year-old girl with CVID and AU was treated with IVIG 400 mg/kg every 4 weeks. Since her second dose of IVIG, regrowth of eyelashes, eyebrows, body and scalp hair was observed in this patient. At present, about 1 year treat-meant of IVIG, significant hair regrowth is noted with 5-6 cm of scalp hair. We believe that IVIG may be beneficial in the treatment of AU, at least in patients with CVID. FAU - Boonyaleepun, S AU - Boonyaleepun S AD - Department of Pediatrics, University of Tennessee Medical Center, Knoxville, USA. FAU - Boonyaleepun, C AU - Boonyaleepun C FAU - Schlactus, J L AU - Schlactus JL LA - eng PT - Case Reports PT - Journal Article PL - Thailand TA - Asian Pac J Allergy Immunol JT - Asian Pacific journal of allergy and immunology JID - 8402034 RN - 0 (Immunoglobulins, Intravenous) SB - IM MH - Alopecia/complications/*therapy MH - Child MH - Common Variable Immunodeficiency/complications/*therapy MH - Female MH - Hair/*drug effects/growth & development MH - Humans MH - Immunoglobulins, Intravenous/*therapeutic use MH - Treatment Outcome EDAT- 1999/07/14 00:00 MHDA- 1999/07/14 00:01 CRDT- 1999/07/14 00:00 PHST- 1999/07/14 00:00 [pubmed] PHST- 1999/07/14 00:01 [medline] PHST- 1999/07/14 00:00 [entrez] PST - ppublish SO - Asian Pac J Allergy Immunol. 1999 Mar;17(1):59-62.